Growth stories are starting to look more interesting again as manufacturing and confidence data across Europe and Asia send mixed but improving signals, while inflation cools in several key markets. In this kind of cross current, many investors are looking for companies where insiders have meaningful skin in the game and where analysts and management share an optimistic outlook. The Fast Growing Stocks With High Insider Ownership screener focuses on exactly that combination. In this article, you will see three stocks from the screener that stand out as potential candidates for further research.
Predictive Discovery (ASX:PDI)
Overview: Predictive Discovery is an Australia based gold company focused on exploring, developing and operating gold projects in West Africa, anchored by its flagship Bankan Gold project in north east Guinea covering 356 square kilometres.
Market Cap: A$3.3b
Predictive Discovery provides exposure to a growing West African gold platform, with two operating mines and the Bankan project moving through detailed engineering and contract awards. The company currently reports no revenue and a loss of A$21.87 million over the nine months to March 2026. Forecasts point to very high earnings and revenue growth over the next few years and analysts see upside to their assessed value. However, the company relies on external borrowing, has less than one year of cash runway and carries a rich P/B multiple. Recent insider selling, planned share consolidation and governance changes also matter for anyone weighing up the risk and reward in this gold producer’s next phase.
Accelerating project progress with no current revenue makes Predictive Discovery a complex story. Before you decide how to treat that mix of promise and pressure, review the 2 key rewards and 4 important warning signs (2 are major!)
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals develops and sells radiopharmaceutical products that help doctors both find and treat cancer, combining precision imaging agents with targeted therapies for prostate, kidney, brain and other solid tumors across multiple global markets.
Operations: Telix Pharmaceuticals generates most of its revenue from Precision Medicine at about US$621.9m, with Manufacturing Solutions contributing roughly US$245.1m and Therapeutics about US$9.3m, alongside smaller sales across China, the United States and other countries and inter segment eliminations.
Market Cap: A$4.9b
Telix Pharmaceuticals is drawing attention because it already sells prostate cancer imaging agents globally while pushing a large pipeline of cancer therapeutics through Phase 3 trials. This gives investors a mix of current revenue and possible future treatment options. The stock has been weak since 2025 despite analyst estimates that suggest meaningful upside and a valuation that screens as cheap on several measures. This may interest investors who like growth stories that have been marked down. At the same time, Telix is still loss making, carries higher risk funding, faces pricing pressure in imaging and depends heavily on positive trial outcomes. That mix of commercial traction and open questions is what makes the next few years for Telix so important for investors watching this theme.
Telix Pharmaceuticals has revenue in the market today but a marked down share price that some investors feel does not reflect the whole story. Get the analyst forecasts for Telix Pharmaceuticals to see what current expectations might be missing.
Lindian Resources (ASX:LIN)
Overview: Lindian Resources is a Perth based explorer focused on rare earths, bauxite and gold, with its flagship Kangankunde Rare Earths project in Malawi and additional exploration exposure across Tanzania, Guinea, Australia and Singapore.
Market Cap: A$1.41b
Lindian Resources is on many rare earths watchlists because Kangankunde is moving toward first concentrate targeted for Q4 2026, while the company is also assessing a processing facility acquisition in Kazakhstan and has opened a Singapore office to bring sales and marketing in-house. At the same time, it is still unprofitable with revenue currently under US$1m, relies entirely on higher risk external borrowing and has experienced heavy shareholder dilution, all under a young board and management team with limited tenure. If you want exposure to a growing rare earths project but also want to understand how those funding and governance trade offs stack up, Lindian’s next steps will be important to follow.
Lindian Resources is racing to bring Kangankunde online, while funding and dilution questions still hang over the story. Get the 1 key reward and 2 important warning signs (2 are major!) to see what could tilt this rare earths bet either way.
The three stocks covered here are only a starting point, as the full Fast Growing Stocks With High Insider Ownership screener surfaced 100 more companies with similarly compelling growth stories and insider alignment that may be worth a closer look. Identify and analyze the specific catalysts and narratives that matter to you by running the Fast Growing Stocks With High Insider Ownership screener.
Take Control of Your Investment Journey
If Telix Pharmaceuticals or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Seeking Fresh Stock Ideas Beyond Today?
New breakout themes often move fast and then cool as attention shifts. Scan these fresh pick lists before the crowd catches on and while the information still matters, act while it is still timely.
- Spot potential value rebounds early by reviewing the curated 7 high quality undervalued stocks that currently combine earnings power with balance sheet strength before momentum sends valuations higher.
- Consider the infrastructure backbone of the AI wave through the hand picked 55 AI infrastructure stocks that could benefit as data centers, chips and networks continue to scale.
- Evaluate the risk of a possible metal supply squeeze by checking the focused 8 top copper producer stocks that screens producers with the capacity to respond if demand changes.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com